Inspired by these breakthroughs in immunotherapies for AD, scientists have developed immunotherapies targeting alpha synuclein [26,54] since alpha synuclein has been identified as the main pathological protein linked to Parkinson’s Disease [55,56,57]. Here, SNCA is linked to Alzheimer disease.